Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

References are made to (1) the announcement of Livzon Pharmaceutical Group Inc. (the "**Company**") dated 23 April 2026 in relation to, among others, the appointment of independent non-executive Director (the "**Appointment Announcement**") and (2) the circular dated 23 April 2026 in relation to, among others, the re-election of independent non-executive Directors (the "**2025 Annual Circular**"). Unless otherwise defined herein or the context otherwise requires, terms used in this supplemental announcement shall have the same meanings as those defined in the Appointment Announcement and the 2025 Annual Circular.

The Board hereby makes the following supplementary disclosure pursuant to Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Each of Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li has confirmed to the Company that:

(i) he or she is independent in respect of each of the factors set out in paragraphs (1) to (8) of Rule 3.13 of the Listing Rules; (ii) he or she does not have any past or present financial or other interests in the business of the Company or its subsidiaries, nor does he/she have any connection with any core connected persons of the Company (as defined in the Listing Rules); and (iii) as at the date of his or her appointment or re-election, there are no other factors that may affect his or her independence.

The information contained in this supplemental announcement does not affect any other information contained in the Appointment Announcement nor the 2025 Annual Circular. Save as disclosed above, all other information in the Appointment Announcement and the 2025 Annual Circular remains unchanged. This supplemental announcement is supplementary in nature and should be read in conjunction with the Appointment Announcement and the 2025 Annual Circular.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Liu Ning
Company Secretary

Zhuhai, China
28 April 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (Vice Chairman); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

* *For identification purpose only*